Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2015

View Archived Issues

AQP-4 inhibition improves survival of cardiac allografts in mice

Levetiracetam shows potential for the treatment of PVL

ISTH-0036 shows potential for the treatment of ophthalmic diseases

Daiichi Sankyo presents interaction study results for mirogabalin besylate

biOasis and partners awarded research grant focused on blood-brain barrier

Juno and Editas collaborate on next-generation CAR T and TCR therapies for cancer

Bayer partners with AACR to fund cancer research fellowships

Empagliflozin/metformin pill approved in E.U. for type 2 diabetes

Prevention of liver fibrosis using hydrodynamic gene delivery of MMP13

Pfizer launches grant program to study palbociclib in breast cancer

Seres Therapeutics doses first patient in C. difficile recurrent infection trial of SER-109

Celldex starts phase I/II trial of varlilumab and sunitinib in RCC

XBiotech cleared to start trial of antibody therapy for S.aureus infection

The Scripps Research Institute receives NIH grant to study novel obesity pathway

Merck & Co. files NDA for grazoprevir/elbasvir for HCV infection

IRM reports development of farnesoid X receptor agonists

Purdue Pharma discloses Nav1.7 sodium channel blockers

University of Montpellier and INSERM jointly patent new HER3 antibodies

Chymase inhibitors prepared and tested at Bayer

Merck & Co. synthesizes antidiabetic FFAR1 agonists

Pacira to conduct additional phase III trials to support sNDA for Exparel

Galenica to commercialize Roche's Mircera in U.S.

European Commission approves intermittent use of Esmya for long-term management of uterine fibroids

EMA validates MAA for emtricitabine/tenofovir alafenamide fumarate for HIV

Preliminary phase I data on PDS-0101 in patients with pre-cervical cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...